Although fewer antibody fragments have entered the clinic than full-length monoclonal antibodies, proof-of-concept studies for these therapeutics remain the main hurdle. Tufts Center for the Study ...

To establish whether molecules other than scFv antibody fragments could be lipid-modified and inserted into cell membranes, we cloned the gene encoding human interleukin-2 (IL-2) into vector pLP2 ...

The use of engineered antibody fragments as biopharmaceuticals has risen recently, with monovalent formats like Fab, scFv, VHHl, and bispecific constructs such as BiTE and Diabody seeing more ...

At the core of this design are nanobodies -- small, highly stable antibody fragments derived from camels. Nanobodies offer remarkable resistance to denaturation in harsh conditions, making them ...

An investigational therapy is demonstrating preclinical promise against non-Hodgkin lymphoma by boosting natural killer cells ...

The French firm will use the proceeds to advance its ALIGATER platform for delivering genetic payloads and move its preclinical assets toward the clinic.

At the core of this design are nanobodies—small, highly stable antibody fragments derived from camels. Nanobodies offer remarkable resistance to denaturation in harsh conditions, making them ...

Bifikafusp alfa + onfekafusp alfa is under clinical development by Philogen and currently in Phase III for Metastatic Melanoma.